Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Reata Pharmaceuticals, Inc. (NASDAQ: RETA).

Full DD Report for RETA

You must become a subscriber to view this report.


Recent News from (NASDAQ: RETA)

Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Reata announces receipt of $30M payment from Kyowa Hakko Kirin
Reata Pharmaceuticals (NASDAQ: RETA ) received a $30M milestone payment from its licensee, Kyowa Hakko Kirin, following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japa...
Source: SeekingAlpha
Date: August, 31 2018 05:25
Reata Announces Receipt of $30 Million Milestone Payment From Kyowa Hakko Kirin
IRVING, Texas, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that it has received a $30 million milestone payment from its licensee, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), following the init...
Source: GlobeNewswire
Date: August, 30 2018 18:40
Rigel Pharmaceuticals: A Look At The Competition
In April the FDA approved Rigel Pharmaceuticals ( RIGL ) fostamatinib (Tavalisse) for chronic immune thrombocytopenic purpura (ITP). I had predicted approval but found myself noting the potential for a sell off soon after. Following approval of Tavalisse, it seemed likely the market’...
Source: SeekingAlpha
Date: August, 28 2018 11:00
Reata Pharmaceuticals: Thesis Strengthened, Q3 Data Looms
Shares of Reata Pharmaceuticals ( RETA ) have risen by 187% since my update article was published in December of last year, suggesting that readers ¨follow the insiders¨ and establish a pilot position. In the last three months alone the stock price has climbed by 140%, aided by p...
Source: SeekingAlpha
Date: August, 24 2018 20:22
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q2 2018 Results - Earnings Call Transcript
Reata Pharmaceuticals, Inc. (RETA) Q2 2018 Results Earnings Conference Call August 08, 2018 04:30 PM ET Executives Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - Chief Medical Officer Jason Wilson - CFO Analysts Maurice Raycroft - Jefferies Adam Walsh - Sti...
Source: SeekingAlpha
Date: August, 11 2018 20:33
Reata Pharmaceuticals misses by $0.35, misses on revenue
Reata Pharmaceuticals (NASDAQ: RETA ): Q2 EPS of -$1.08 misses by $0.35 . More news on: Reata Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 08 2018 16:55
Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs
IRVING, Texas, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product development programs and announced financial results for the second quarter ended June 30, 2018. Prod...
Source: GlobeNewswire
Date: August, 08 2018 16:01
Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018
IRVING, Texas, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and live webcast on Wednesday, August 8, 2018, at 4:30 p.m. ET to report its second quarter 20...
Source: GlobeNewswire
Date: August, 06 2018 17:35
Behind The 'Knee-Jerk' Sell-Off In T2 Biosystems
I come from a home where gravy is a beverage .” ― Erma Bombeck The late summer continues to see a dismal market for many small biotech and medical device stocks. The third quarter is often the worst quarter of the year for this sector as volume dries up, there are few maj...
Source: SeekingAlpha
Date: August, 05 2018 09:23

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0884.6584.0786.7683.725178,107
2018-05-2131.8031.8532.1531.2074,052
2018-05-1831.9831.5532.6231.11165,269
2018-05-1732.0832.1332.3931.64112,400
2018-05-1630.6532.0232.0930.62199,952

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1216,07132,38149.6310Short
2018-12-1133,50669,69648.0745Short
2018-12-1043,14270,96960.7899Short
2018-12-0734,27061,18556.0105Short
2018-12-0635,19453,80765.4078Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RETA.


About Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Logo for Reata Pharmaceuticals, Inc. (NASDAQ: RETA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $634,911,905 - 05/11/2018
  • Issue and Outstanding: 19,990,929 - 02/28/2018

 


Recent Filings from (NASDAQ: RETA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 10 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 02 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 02 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 01 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: December, 29 2017

 

 


Daily Technical Chart for (NASDAQ: RETA)

Daily Technical Chart for (NASDAQ: RETA)


Stay tuned for daily updates and more on (NASDAQ: RETA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: RETA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RETA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RETA and does not buy, sell, or trade any shares of RETA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/